Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Older people with undiagnosed dementia who get hospitalized experience worse outcomes than other groups of older adults who require hospitalization, a study by Halima Amjad, a dementia and geriatrics expert at Johns Hopkins, and colleagues has shown. Amjad: Focusing on …
Podcast: Download (Duration: 1:05 — 1.5MB)
Subscribe: RSS
People who have dementia frequently aren’t diagnosed, and when such a person is hospitalized they are at much higher risk for poorer outcomes. That’s the focus of research by Halima Amjad, a geriatrics and dementia expert at Johns Hopkins. Amjad: …
Podcast: Download (Duration: 1:05 — 1.5MB)
Subscribe: RSS
High blood biomarkers for Alzheimer’s disease found by the newly FDA approved blood test indicate the presence of two proteins in the brain called amyloid and tau. Abhay Moghakar, a neurologist and blood biomarkers expert at Johns Hopkins, says some …
Podcast: Download (Duration: 1:05 — 1.5MB)
Subscribe: RSS
Let’s say you’ve taken the newly approved blood test for Alzheimer’s disease and the results indicate the presence of tau and amyloid in your brain, so you’re at risk. Abhay Moghakar, a neurologist and blood biomarkers expert at Johns Hopkins, says …
Podcast: Download (Duration: 1:06 — 1.5MB)
Subscribe: RSS
A new blood test for Alzheimer’s disease isn’t a stand alone diagnostic tool. That’s according to Abhay Moghekar, a blood biomarkers expert and a neurologist at Johns Hopkins. Moghekar: You would still need the clinical input in the context of …
Podcast: Download (Duration: 1:04 — 1.5MB)
Subscribe: RSS
Will an FDA cleared blood test for Alzheimer’s disease ease or complicate diagnosis? Clearly in approving the test the FDA hopes for the former, yet the complete picture is more complex than that, says Abhay Moghekar, a blood biomarkers expert …
Biomarkers alone don’t mean Alzheimer’s disease is present, Elizabeth Tracey reports Read more »
